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Abstract
Parkinson’s Disease is a common neurodegenerative disease affecting one’s ability to
hone and refine volitional movement. Many with Parkinson’s report significant effects on voice
and communication. Speech-language pathologists have long targeted the achievement of
increased vocal volume through intensive voice therapy, with the most common program being
Lee Silverman Voice Treatment® (LSVT®) (Ramig et al., 1994). While LSVT® is the most
prominent type of voice therapy for individuals with Parkinson’s, other researchers have begun
investigating therapeutic singing because of the similar functions it employs (e.g., increased
breath support, utilization of entire vocal range).
The current project is a retrospective, longitudinal study that aims to observe effects of
singing in conjunction with LSVT®. Researchers followed a trained singer with Parkinson’s
disease who underwent LSVT® for four years to observe vocal performance across time. First,
this study aimed to identify if there is a relationship between frequency of singing and vocal
performance. Secondly, because Parkinson’s disease is neurodegenerative and symptoms
worsen over time, this study charted vocal progress and identified any influencing factors that
would increase or decrease vocal performance and intelligibility. Researchers measured vocal
intensity and pitch ranges at monthly intervals while also collecting subjective data including
report of any health or social changes.
Results showed frequency of proper singing affected maintenance and even
improvement of vocal performance in intensity and pitch ranges and intelligibility, though not
always consistent. Inversely, as expected, a decline in mobility, overall health, and medication
was shown to negatively affect vocal performance. This study is an introductory look into how
vocal performance and intelligibility are affected by various factors. Thus, this project will inform
further research investigating appropriate voice treatment for individuals with Parkinson’s
Disease.
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Introduction
Communication serves individuals with the ability to inform, to convey wants and needs,
to persuade, and to socially interact. Communication is significantly altered in those with
Parkinson’s disease (PD), specifically through decline in both volume and pitch ranges when
speaking. The present study concentrates on investigating trends of vocal performance and
different variables that might impact vocal maintenance in PD. Vocal maintenance, in this study,
is defined by performance on various singing and speaking tasks including maximum phonation
time, pitch range, amplitude range, and intelligibility/audibility in conversation. We aim to seek
the effect consistent singing has on vocal maintenance as well as chart vocal quality across
time through a retrospective, longitudinal case study.
Parkinson’s Disease
Parkinson’s disease (PD) is a neurodegenerative disease affecting neurons in the basal
ganglia deep within the brain, particularly the substantia nigra, the area that produces
dopamine. In Parkinson’s disease, these dopaminergic (dopamine producing) neurons die. The
basal ganglia are part of our extrapyramidal system that produces refined, smooth purposeful
movement. With decreased dopamine production, the basal ganglia cannot function properly in
honing our skilled voluntary movement. This leads to the hallmark symptoms of PD including
bradykinesia (slow movement), tremor at rest (commonly a “pill-rolling” tremor of the forefinger
and thumb), rigidity, and postural instability and imbalance (Mayfield Clinic, 2018). Other
potential symptoms of Parkinson’s disease are shuffled gait, stooped posture, cognitive
impairment, difficulty swallowing, excessive drooling, difficulty speaking, pain, loss of smell,
dementia, and hypomimia (masked expression) (Parkinson’s Foundation, 2018). These
symptoms may progress slowly or quickly, depending on the severity of the disease and are
both motor and non-motor in nature.
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While every individual with PD presents and develops symptoms differently, there are
typical markers of disease progression. Early upon receiving the diagnosis, the individual will
likely notice the symptoms, but symptoms will not interfere with activities of daily living (ADL).
Initial symptoms include handwriting becoming smaller, stooped posture, and more difficulty
making facial expressions, and these symptoms tend to be unilateral. Further along, the
individual will be at a higher risk of falls due to imbalance issues, will have slower movements,
and more difficulty with speech. During the latter development of the disease, individuals will no
longer be able to live independently, will need help with ADL and are limited to a bed or
wheelchair. However, it is not always the case that every individual will progress to this level of
symptomatology. In 1967, Hoen and Yahr developed a staging scale to quantify the decline of
Parkinson’s disease, called the Hoen-Yar scale. It ranges from stages I-V, with I including
unilateral involvement only, usually with minimal or no functional impairment, to V having the
individual confined to their bed or wheelchair unless aided. In general, individuals will progress
through the stages though some will never reach stage V. Another scale for staging PD is the
Unified Parkinson’s Disease Rating Scale (UPDRS). Rather than rating the severity of
symptoms overall, this scale clusters symptoms and rates each grouping on a scale from 1-4,
with 1 being the mildest and 4 being the most severe. These groupings include intellectual
function, ADL, motor examination, and assessment of motor complications, including dyskinesia
and/or motor fluctuations. Due to the variable nature of this disease, there is not a typical
progression of symptomatic experience.
Today, Parkinson’s disease affects roughly 1 million Americans and 10 million people
worldwide. Every year, approximately 60,000 Americans are diagnosed with PD (Parkinson’s
Foundation, 2018). Within those diagnosed, an estimated 89% experience difficulty with their
speech (Trail et al., 2005).
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Hypokinetic Dysarthria

Classic speech symptoms of PD are classified as a form of hypokinetic dysarthria. As
defined by Darley, Aronson, and Brown (1969), the cluster of symptoms common to hypokinetic
dysarthria includes hoarse, harsh, breathy voice, decreased pitch, increased rate of speech,
imprecise consonants, and distorted vowels. A distinctive characteristic of this dysarthria is the
rapid rate, which causes “blurred” or mumbled speech. People with hypokinetic dysarthria often
also display hypophonia, or diminished speech intensity. They speak at a much quieter volume
because of a sensorimotor deficit resulting in improper auditory feedback. Due to this deficit,
individuals feel as if they are speaking louder than they actually are, creating difficulty with
producing audible speech (Andreetta, Adams, Dykstra, & Jog, 2016). Other speech changes
associated with hypokinetic dysarthria include a decrease in variability within fundamental
frequency of connected speech. A study conducted by Bowen, Hands, Pradhan, and Stepp
(2013) discovered a significant difference depending on medication and when compared to
healthy controls. When subjects with PD were using dopaminergic drugs, their variability of
frequency increased. However, when comparing both PD groups (on or off medication) to
healthy controls, individuals with PD demonstrated a decrease in variability regardless of
medication status (Bowen et al., 2013).

Research conducted by Kempler and Van Lancker (2002) demonstrates how hypokinetic
dysarthria in PD affects intelligibility differently for different speech tasks. They evaluated
intelligibility across five speech production tasks (spontaneous speech, reading, repeated
spoken and singing, and spontaneous singing) in an individual with PD. Sixty-four novel
listeners listened to the subject’s five speech samples and transcribed the samples they heard.
Researchers discovered the mean percentage of intelligibility varied for the tasks. Participants
were able to correctly identify 29% of spontaneous utterances, 78% of read utterances, 79% of
repeated spoken utterances, 80% of repeated sung samples, and 88% of spontaneously sung
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samples. The intelligibility of conversational speech is significantly less than other
speaking/singing tasks. Researchers highlight the “identifiable differences” of the production
tasks in relation to initiation of the movement: the spontaneous samples requiring internally
generated models of the target production versus the read or repeated samples having a model
provided. Existing research in relation to musculoskeletal limb movements reports that
movement is more fluid when there is a model provided or when the cognitive load of initiation is
reduced (Kempler & Van Lancker, 2002). In the repeated tasks or read tasks, the cognitive load
is reduced because there is a provided model of the target, and researchers propose that the
research on musculoskeletal movement can be applied to articulatory placement and production
of speech. This explanation does not, however, elucidate the occurrence of increased
intelligibility of the spontaneous singing task. Based on the aforementioned initiation theory, the
spontaneity of the task should require a similar overall motor plan as spontaneous speech and
thus, actually decrease intelligibility. A potential factor to explain the intelligibility of spontaneous
singing is that singing requires increased respiration which is also associated with increased
volume and clarity. Also, when singing, even spontaneously, individuals utilize continuously
varying prosody or inflection, also known as “pitch contours”. Researchers note that this
chunking of larger units lowers the demand for “initiation of internal sequences” and thus,
ongoing movement is smoother. Kempler and Van Lancker (2002) hypothesize that the
combination of these two factors (i.e. increased respiration and continuous pitch contours)
accounts for the increased intelligibility of the spontaneous singing condition. Research cited by
Kempler and Van Lancker (2002) compares people with aphasia (PWA) and people who stutter
(PWS) in speech versus singing conditions. It shows that both groups tend to perform better on
singing tasks than speech tasks. This signals that perhaps singing and speech are primarily
controlled from “different brain mechanisms.”
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To further understand why spontaneous singing was more intelligible compared to
spontaneous utterances, consider Luria and Vygotsky’s research on Parkinson’s (Moskovich,
Bougakov, DeFina, & Goldberg, 2002). Researchers conducted studies on individuals with PD
who had difficulty walking and had an increase in falls. Luria and Vygotsky aimed to examine if
engaging different sensorimotor areas than is typical for such an automatized function as
walking, would increase smoothness of gait. Luria and Vygotsky increased cortical control of the
task by instructing patients to step over pieces of scattered paper on the floor. Thus, deautomatizing the task, and researchers were hopeful that would increase higher level
sensorimotor activity. They found that they were, in fact, able to recruit higher neural functioning
that compensated for an impaired automatized process, resulting in improved gait (Moskovich et
al., 2002). This thought could be applied to the Kempler and Van Lancker (2002) study, as
speaking generally begins to occur a similar time as walking. It could be argued that speech is
equally as much of an automatized action. Perhaps by incorporating higher cortical processes
through thoughts of inflection and increased respiration, individuals are then able to overcome
any impairments producing more intelligible utterances.

As shown above, intelligibility is affected differently based on the speech task. From the
research by Kempler and Van Lanker (2002), we see that hypokinetic dysarthria in PD most
severely affects spontaneous utterances, which consequently, is the most frequently used
condition in natural settings. These dysarthric deficits affecting spontaneous speech are shown
to create a decline of communication for people with PD, consequently affecting their quality of
life. Across two studies conducted by Miller and colleagues, (Miller, Noble, Jones, & Burn, 2006;
Miller, Noble, Jones, Allcock, & Burn, 2008), researchers surveyed 213 people with PD and
caregivers about the implications of PD on their communication. They reported that 90% of
responders noted how PD impacts a person’s willingness to speak up and initiate conversation
before any articulatory issues even arise. This hesitancy to engage in conversation is known to

5

have adverse effects on the individual’s quality of life (Shih et al. 2012). As a result, researchers
desired to examine the breakdown of speech in individuals with PD to further inform proactive
treatment.

Speech impairment in PD

In 2013, Skodda and colleagues attempted to analyze the progression of speech
impairment in individuals with Parkinson’s disease. Participants were recruited from 2002-2012,
including 80 individuals diagnosed with idiopathic Parkinson’s disease and 60 age-matched
healthy controls. Researchers aimed to monitor the changes in voice and speech performance
on sustained vowels and connected speech tasks. Subjects were first examined upon their
intake, and then again at a minimum of 12 months later. At both evaluations, participants
underwent a neurological examination and received a Unified Parkinson’s Disease Rating Scale
(UPDRS) Motor Score (including a speech component) and a Hoen-Yahr rating at both visits.
Skodda et al. (2013) compared participants with PD (ages ranging from 40-80) to their age
matched peers on their UPDS perceptual speech score. At baseline, they found that participants
with PD scored worse than their age matched peers. When evaluating the two groups across
time, they found that participants with PD showed a significant decrease in overall UPDS
perceptual score as well as within individual speech modalities (voice, articulation, fluency,
prosody), whereas the control group showed no such differences. Their research also revealed
a correlation between speech deficits and the participants’ Hoen-Yahr stage of PD. Skodda et
al. (2013) found the farther along the individual was in their Hoen-Yahr staging, the worse the
speech symptoms were. Because of the progressive nature of the disorder and the negative
communication symptoms associated, clinician-researchers desired to determine an effective
course of treatment for Parkinson’s Disease. The primary methods investigated are both
medication and rehabilitative therapy, which have the potential to both slow and reverse some
symptoms (Hinz, Stein, Cole, McDougall, & Westway, 2016). Speech therapy techniques have
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been thoroughly researched and shown to have positive results combatting vocal decline in
Parkinson’s disease. Speech-language pathologists have long targeted the achievement and
maintenance of increased speaking intensity in patients with Parkinson’s disease due to the
hallmark PD characteristic of quiet speech (Scott & Caird, 1983; Robertson & Thompson, 1984).
In 1994, this technique was standardized and formalized as an official treatment.

Treatment

Lee Silverman Voice Treatment (LSVT®)

Dr. Lorraine Ramig (1994) developed the Lee Silverman Voice Treatment (LSVT®)
program to target maintaining increased intensity while speaking with increased breath support.
It consists of emphasizing loud speech in individual therapy sessions, four days a week, for four
consecutive weeks. During these therapy sessions, the individual will practice a loud voice for
sustained vowels, glides up and down their full pitch range, frequently-used functional phrases,
as well as gradually increasing the length of utterance. These are all maximum effort tasks, with
the phrases and conversation pieces being the most functional for communication. The
individual is also encouraged to practice exercises daily outside of the therapy session to gain
the highest benefit from the program. LSVT® encompasses 3 main foci in treatment: (1) it
specifically targets increased amplitude to enhance voice and to trigger improved articulation,
vocal quality, intonation and reduced rate, (2) it focuses on recalibrating the patient’s perception
of their own loudness to reinforce that they are, in fact, communicating within normal limits
although they may feel loud, and finally (3) it targets increasing self-cueing to facilitate
generalization of these practices and continued use of increased volume outside the therapy
setting (Fox, Ebersbach, Ramig & Sapir, 2011).
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In 1995, Dr. Ramig and colleagues investigated the effect of her LSVT® treatment
methodology as compared to intensive speech therapy targeting respiratory muscle activity
alone. Forty-five subjects split into the two treatment groups and underwent the same amount of
therapy for a month in their respective conditions. Researchers measured intensity and duration
during maximum sustained phonation, as well as intensity, habitual frequency and variability of
fundamental frequency during connected speech. They also took pre- and post-treatment selfratings in a patient and family questionnaire rating perceptual variables and inquiring to what
degree Parkinson’s disease affects their communication. Results showed a significant increase
in pre- and post- treatment across more measurements and with greater magnitude for the
LSVT® group as compared to the controls. The subjects in the LSVT® condition reported a
significant decrease in the effect PD has on their communication. Researchers reported that
variables such as stage of disease, severity rating, and time since diagnosis did not predict
effectiveness of treatment. Overall, results display that intensive treatment focusing on
respiration paired with phonation (i.e., LSVT®) is more effective than simply targeting respiration
alone for increasing vocal intensity and decreasing the negative impact PD has on
communication (Ramig, Countryman, Thompson, & Horii, 1995). This early research shows the
effectiveness of LSVT® immediately after treatment but does not show long-term effects of the
treatment approach.

In 1996, Ramig et al. then conducted further research to determine both the
effectiveness of LSVT® and the extent that the positive effects of LSVT® would remain. They
measured 35 subjects assigned to one of two conditions: targeting respiration alone or LSVT®.
They measured vocal intensity at pre- and immediately post- treatment and again at 6- and 12months post-treatment. They found that only subjects in the LSVT® group maintained gains
above pre-treatment levels after the 12 month period (Ramig, Countryman, O’Brien, Hoehn, &
Thompson, 1996). Ramig and colleagues conducted a similar study again in 2001, this time
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including a measurement of 24 months post-treatment. The researchers measured intensity and
inflection in fundamental frequency across time. The LSVT® group was found to be statistically
significant in improving and maintaining both intensity and inflection immediately post-treatment
and 24 months post-treatment. The results of measures taken at 6- and 12-months posttreatment were not included in this study. This combined research shows the longevity of
LSVT® treatment in relation to intensity and fundamental frequency, but no measures of
connected speech tasks were included.

Researchers Wight and Miller (2015) attempted to bolster the existing research by
providing additional measures to evaluate change after LSVT®, including connected speech
tasks. They measured maximum intensity (in dB) and duration of sustained phonation, habitual
intensity (in dB) of connected speech tasks, and a self-rated Voice Handicap Index (VHI). These
measures were recorded immediately after receiving LSVT®, and again at 12- and 24-months
post treatment. They found that all gains were maintained 12 months after completing LSVT®.
Improvements in duration of sustained phonation were maintained at 24 months post treatment.
Connected speech scores, however, reflected closer to baseline when measured at 24 months
post-treatment showing that significant progress was not maintained from initial treatment
(Wight & Miller, 2015). Their reports on the Voice Handicap Index (VHI) reflect a similar trend of
returning back to baseline at 24 months post-treatment.

Along with the increases in acoustic measures, studies have shown physiological
changes immediately after treatment including: larger excursion of the rib cage when breathing
for speech, increased subglottal pressure, and stronger and more symmetrical closure of the
vocal folds (Fox et al., 2011). Other positive changes from LSVT® include improved consonant
articulation, facial expression, tongue strength, rate of speech, and some improvement in the
oral phase of swallowing (Fox et al., 2011). Finally, perceptual ratings of speech also showed
improvements. Participants who completed the program showed a decrease in vowel
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centralization and increase the quality of vowels (Sapir, Spielman, Ramig, Story, & Fox, 2007;
Sapir, Ramig, Spielman, and Fox, 2010). Listeners also rated improved loudness and vocal
quality immediately after participants received treatment (Fox, Morrison, Ramig, & Sapir, 2002).
While extensive research over the past 24 years shows the LSVT® program’s clinical
merit, there are limitations, including the potential for publication bias as well as relatively small
sample sizes (Tomlinson et al., 2014). The most significant clinical weakness thus far, is the
challenge of maintaining vocal gains following LSVT® due to the nature and progression of PD.
Because of this, researchers have begun examining other approaches containing similar
elements to that of LSVT® to explore potential treatment methods for PD. Singing, for example,
targets proper abdominal breathing, sustained phonation, and incorporates the individual’s full
pitch and dynamic ranges. While these tasks are not functional for treating communication
directly, they share elements with tasks of maximum phonation time and pitch range tasks in the
LSVT® protocol. The differences between singing and LSVT® tasks lie primarily within targeting
speech intelligibility. LSVT® targets commonly used phrases, monologue, and increases
progression toward using a strong voice in conversational speech, whereas singing does not.
Because of the similarities between the two, though, researchers desire to see if utilizing singing
from a therapeutic approach can have similar benefit to people with PD that LSVT® does.

Therapeutic Singing

Shih et al. (2012) measured the effects of group-based singing intervention on 15
subjects. They underwent choral therapy sessions for 12 weeks, being required to attend at
least 10 out of the 12 sessions. These therapy sessions consisted of 10 minutes of stretching,
10 minutes of vocal exercises, and 70 minutes of singing familiar songs. The sessions were
administered by an SLP and a singing instructor experienced in working with patients with PD.
Subjects were provided with handouts outlining practice procedures and exercises to be
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completed during the week outside the group therapy sessions. Measures were taken at
baseline and then again at 12 weeks when treatment ceased. The primary outcome measure
was vocal loudness and secondary measures were pitch range, phonation time, maximum
loudness, voice related quality of life (VRQOL) as well as the VHI. No speech intelligibility
measures were taken, and there was no inclusion of other factors that may contribute to the
progression or decline of the individuals’ voice symptoms. After treatment, no significant
difference was found between pre- and post-treatment across any measures taken.

In another study conducted by Stegemöller, Radig, Hibbing, Wingate, and Sapienza
(2017), researchers proposed that the inclusion of a more engaging treatment approach could
simultaneously combat attrition, increase motivation and practice outside of therapy, increase
quality of life (QOL), all while improving vocal function. In their study they assessed voice,
respiratory control and QOL after participating in therapeutic singing. Their 27 participants
engaged in therapeutic group singing for 8 weeks, either in a low dose setting (1 hr 1x/wk) or a
high dose setting (1 hr 2x/wk). Participants were not classically trained singers and had not
received any speech therapy within the past 2 years. Nine participants had received LSVT® in
the 5 years prior to the study, but did not continue engaging in the LSVT® exercises posttreatment. The singing intervention was administered by board-certified music therapists.
Intervention targeted vocal intensity, vocal range, articulation, facial expression, and proper
breathing through a variety of vocal exercises for warmup and group singing of familiar songs.
Researchers took voice measures at pre- and post-treatment of sustained phonation, maximum
inspiratory and expiratory pressure, intensity, range, and quality of life. Results did show a
significant increase in both inspiratory and expiratory pressures along with an increase in
sustained phonation of /a/. Individuals’ quality of life was shown to have improved between preand post-testing as well. There was not, however, a statistically significant difference in other
vocal measures including intensity measured in decibels, duration of /i/, and range measured in
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semitones. Furthermore, there was no inclusion of measures to assess intelligibility or any effect
of participant’s speech. This study noted that therapeutic singing can have a positive effect on
quality of life, but further research on the interaction of singing and PD symptoms is needed to
determine if it can be used to increase intelligibility.

Current Study

The primary purpose of the current study is to evaluate the long-term functioning of a
trained singer with PD who underwent LSVT® and attended monthly follow-up sessions to
monitor vocal performance on a variety of tasks. Variation in singing and speech performance
will be assessed across time. Any indications of vocal decline will be identified. For this project,
subjective ratings of intelligibility and vocal quality as well as objective measures such as
amplitude and pitch, maximum phonation time were considered as vocal maintenance. Specific
research questions include:

1.

Does frequency of singing practice increase maintenance of performance on

speech/singing tasks including pitch range and audibility?

2.

How are pitch range, audibility, and intelligibility affected by disease progression and other

social/environmental factors?

This retroactive longitudinal case study will bolster the existing research by providing
additional data, including both quantitative and qualitative longitudinal measures. By isolating
variables affecting voice both positively and negatively, further research with larger studies
could examine the variables in question. Practicing speech-language pathologists will then be
able to utilize this information to more thoroughly educate their patients and families of people
with PD. The hope is this study to maintain both research and clinical merit.
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Methodology
Subject

This project involves one adult male PA, age 89, who began experiencing symptoms of
Parkinson’s disease in 2012 at the age of 82. His son had been diagnosed with PD several
years earlier, making him aware of the early PD indicators he was experiencing. Although he
was not experiencing the classic tremor, he was diagnosed shortly after reporting symptoms.
PA was referred for LSVT® in February 2014 by his Ear Nose and Throat (ENT) physician who
noticed a reduction in loudness and intelligibility in conversation. His speech diagnostic was
conducted at a private practice clinic. At time of evaluation, PA was at the PD Hoehn-Yahr stage
2 (bilateral or midline involvement without impairment of balance). He displayed loss of facial
expression, bilateral stiffness, slow movement, reduction of spontaneous movements, and
difficulty with speech. He did not experience tremor and was capable of completing all activities
of daily living. PA is a trained singer and has been singing from an early age. At the time of
evaluation, he sang up to 5 times each week, performing in barbershop quartets and church
choirs. PA did not report significant awareness of his speech changes but reported a decrease
in pitch range when singing. He also reported others having difficulty hearing him and difficulty
being understood on the telephone. Upon evaluation, PA had not yet begun physical therapy for
assessing and treating gross motor movement. He began Lee Silverman Voice Treatment on
March 5, 2014.
Reports indicate successful completion of the LSVT® program. PA’s wife is his main
communication partner and was considered a potential obstacle to progress due to his report
that she consistently demonstrated a quiet voice. It was noted that the PA did not perform
homework as requested due to his wife’s objections that he was too loud. PA later stated that he
attempted to match the loudness of others and felt he was able to adjust appropriately. Due to
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PA’s age and concerns regarding maintenance of his ability to communication and sing, he
attended monthly sessions to monitor his speech and singing.

Measurements/Data Collection
Monthly data of PA’s vocal capability was collected at a University Speech and Hearing
Clinic by a certified speech language pathologist (SLP) who specialized in voice disorders. This
data spans across the dates of PA’s first and second participation in LSVT®, from February
2014 to May 2018). Records of his performance during follow-up sessions on various LSVT®
and singing tasks were used to obtain subjective and objective measures. Any variation in these
measures that corresponds to disease progression will be identified. All measures were
collected in a quiet therapy room.

Subjective measures

At the beginning of each session, PA practiced loud speech in conversation, in
monologue, and in frequently used functional phrases. Functional phrases were previously
determined by primary SLP and PA. Perceptual characteristics of PA’s vocal quality, audibility,
and intelligibility were subjectively judged in conversation, monologue, and in functional
phrases. This dialogue served as a sample to rate the subject’s voice on the GRBAS rating
scale. This scale represents: Grade, Roughness, Breathiness, Asthenia, Strain, and rates each
measure on a scale of 1-3, with 0= normal, 1=slight degree, 2=medium degree, and 3=high
degree. PA reported any changes in his perceived singing and speaking ability, such as vocal
quality, range, pitch, and volume. PA noted frequency of singing practice and health or
social/environmental changes, as well as his spouse’s report of change in audibility or
intelligibility. PA also reported his medical condition/status and other relevant symptoms or
treatments, including gross motor ability, physical therapy, and general health.
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Objective measures

Sustained phonation of vowels for maximum phonation time (MPT) was measured with
an average of four vowels being reported. PA was instructed to hold /a/, /i/, /u/, and /o/ for as
long as he could, using a loud, strong voice. MPT was recorded on a stopwatch. PA then
performed pitch glides up and down the scale at a loud volume with various vowels. This was
utilized as a warmup before recording his voice range profile (VRP). Finally, a singing measure
of pitch range and dynamic range was recorded on the Computerized Speech Lab (CSL) by
PENTAX Medical hardware with VRP software, generating PA’s VRP. Within the VRP, range of
intensity, or amplitude, was recorded in dB SPL, and range of fundamental frequency, or pitch,
was recorded in Hz. Pitch range includes both total semitones and fundamental frequency. VRP
results were obtained with PA standing in a position he indicated was similar to that used when
singing, with the microphone at a 45-degree angle in a stand placed at a distance PA
determined was comfortable. A constant mouth-to-microphone distance was not reported, due
to changes in PA’s ability to maintain position as his disease progressed. PA indicated that he
did not feel comfortable using a head microphone.

Analysis
After gathering and compiling each month’s objective and subjective measures, multiple
variables were analyzed in attempt to discover any potential relationships. PA’s voice range
profile including maximum, minimum, and ranges of both frequency and amplitude were charted
to show trends of growth or decline across time. Frequency range paired with amplitude range
demonstrates vocal control; specifically, the larger the amplitude ranges, the more control PA
maintains over his vocal volume.
PA’s performance on these ranges will first be compared to norms for frequency and
amplitude ranges as set by Hallin, Fröst, Holmberg, & Södersen (2012). These norms were
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created with 30 healthy male controls and are shown in Table 1. The standard deviation for
frequency range in Hz was not included in the paper.
Table1
Frequency and Amplitude norms on VRP - Hallin, Fröst, Holmberg, & Södersen, 2012
Mean Min (SD)

Mean Max (SD)

Mean Range (SD)

Frequency (in Hz)

76.4 (12.33)

811.3 (209.21)

735 Hz

Amplitude (in dB)

43.6 (3.65)

109.3 (1.77)

67.7 (4.11)

Once the VRP data points were charted, they were then compared against MPT and
subjective measures including GRBAS scales, overall intelligibility, and self-reported variables
such as frequency of singing, medication changes, mobility, general health, other therapies, etc.
Researchers evaluated if frequency of singing practice increased performance or maintenance
of pitch range, amplitude range, maximum phonation time, and/or intelligibility/audibility in
conversation. Then, subject report of severity of PD (i.e., general mobility, cognitive changes,
dysphagia or excess saliva, facial expression, or other health factors) was overlaid on the charts
to evaluate if singing performance reflected indicators of disease progression. Subject report of
health and social/environmental factors including mobility, activity level, social interaction or
hobbies was also taken into consideration. These factors were compared with vocal
performance to see if an increase or decrease in those factors would be mirrored by
performance vocal on tasks during the monthly sessions. This showed if there is a relationship
between health or social/environmental factors and any variation in speech and singing tasks.
Researchers aimed to identify any change in variables indicating that the LSVT® program
should be reintroduced. Evaluating such data points will provide answers to the proposed
questions and shed light on the effect of Parkinson’s Disease on an individual’s voice over time.
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Subjective profile of participant
In order to provide a more robust understanding of how PA’s vocal function fluctuated
across the study and how that corresponded with any objective measures, all subjective report
was gathered and complied in chronological order. At each session PA provided subjective
information regarding vocal performance, frequency of singing practice, any changes in health
status, spousal report of voice changes in PA, and any other potentially relevant factors PA
experienced.
PA did not consistently report subjective measures at each follow-up session but was
able to note changes regarding his health and other contributing factors. He performed variably
on speech and singing tasks periodically throughout the sessions. As a general note, the
frequency of PA’s singing was consistent, ranging up to 5 times per week, in men’s groups,
barbershop quartet, and a church choir. He reported increased singing during the Easter and
Christmas holidays with his church choir. Throughout all sessions, whether sitting or standing,
PA exhibited proper abdominal breathing during speech and singing.
PA described his vocal function as being relatively consistent, but still displaying
increases and decreases throughout this project. He reported on numerous occasions an
awareness of his low vocal volume and the need to match others’ loudness in conversation.
Despite his wife vocalizing her aversion toward his loud practice, upon noticing a decline in his
voice, she began to speak louder herself in order to provide an adequate model for PA.
On February 26, 2014 during the intake appointment, his wife reported that she “can’t
hear or understand him consistently.” PA noted that he becomes “short of breath when singing”
and reported a loss of vocal range. Subject employs a compensatory strategy of reducing rate
to increase intelligibility. He reported no issues of dysphagia but occasional pooling of saliva
and anterior spillage. He displayed no mobility issues at this time. Maximum sustained
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phonation was 12 seconds with a range of 9-12 seconds. He maintained adequate voicing
during all tasks this session, including reading more linguistically complex sentences. His pitch
range was not recorded through the Voice Range Profile during this session but he
demonstrated 21 semitones and showed minimal variation in loudness.

On March 5, 2014, the clinician determined a target loudness for sustained phonation to
reach 80-85 dB. He appeared to match his wife’s vocal volume and clinician observed PA’s wife
to speak quietly. PA reported understanding protocol for LSVT® and committed to practicing.

At the next session, March 19, 2014, PA reported practicing vocal exercises without his
wife and attempting to increase his volume during practice. PA successfully demonstrated a
volume of 80-85 dB during sustained phonation. He utilized a strong, intelligible voice
throughout the session. Toward the end of the session, he spoke on the telephone and reverted
back to a quiet, rapid rate.

In the beginning of April 2014, PA displayed 24 semitones when assessing dynamic
range, showing an increase of 3 since the intake session. Minimal verbal cues were required to
maintain appropriate volume and he demonstrated the ability to maintain a loud voice during
more complex stimuli this session. PA’s wife was also noted to have increased her speaking
volume than in previous sessions.

On April 24, 2014, PA arrived to the session utilizing an adequate volume for speech. He
maintained vocal loudness in conversation for seven out of eight conversational turns. Subject
reported consistent practice following prior session and noted that speaking with an adequately
loud voice feels more natural than when first initiating therapy.
After the above spring sessions, PA’s overall performance and maximum phonation time
on various vowels remained steady through September 2015 maintaining approximately 12
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seconds (range 9-12 seconds). No notable changes in intelligibility or vocal performance noted
by PA or spouse.

September 16, 2015, PA reported taking a new medication for secretion management.
He noticed extreme dryness in his mouth and on his face. He reported “wandering at night” as
another side effect from the medication. His wife reported PA using a quieter voice at home
since starting the medication. On the GRBAS this session, he was rated as G1R1B1A1S0,
showing slight roughness, breathiness, and asthenia. Though the medication had begun to take
effect, these GRBAS scores were observed to be due to wet hoarseness associated with
increased secretions in the mouth. In conversational speech, he demonstrated a slight increase
in rate of speech. Some utterances were inaudible when he spoke on extended breath units. His
maximum phonation time was 7 seconds, ranging from 5-7 seconds and demonstrated only
slight variation in loudness. The session ended prematurely due to drastic effects of new
medication on vocal performance. Clinician determined that the decreased vocal performance
was due to side effects from the medication.

Less than a month later on September 30, 2015, he returned back to the clinic for a
closer follow-up due to the prior medication effects. PA began preventative physical and
occupational therapy, prior to worsening symptoms. Spouse again discussed his difficulty with
maintaining loud vocal volume in the home, but PA felt his wife had a hearing impairment. Upon
further investigation, spouse’s hearing loss was verified which accounted for the discrepancy
between subject and spousal reports. PA noted attempting to match others volume in social
situations, particularly in his men’s singing group. While the drying side effects of his medication
were still present at this time, PA reported them to be less significant. His performance
improved slightly from previous session. His GRBAS rating was 0 for all measures, exhibiting no
roughness, breathiness, asthenia, or strain. For maximum phonation time, both average and
range were 7 seconds. PA demonstrated appropriate vocal loudness during the session. He
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adequately matched the loudness of clinicians during conversation as well as adjusted to the
distance of any listeners.

The following month, October 2015, PA described positive results from physical and
occupational therapy. His wife also reported not having any difficulty hearing or understanding
him and that utilizing a louder voice increased intelligibility. His GRBAS ratings were unchanged
at 0, reflecting a perceptually normal voice. His maximum phonation time was again 7 seconds
during all trials, with no variation between phonemes.

For the next consecutive months, PA remained relatively stable. He continued to
demonstrate ratings of G0R0A0B0A0S0 and 7 seconds with his maximum phonation time,
ranging from 5-7 seconds for most sessions. Early in 2016, PA reported that he and his wife
would be moving to an assisted living community soon but did not actually occur until fall 2016.
This move was of relevance because he and his wife became slightly less independent at the
living community. Prior to the move, PA remained active in and outside the home, doing
yardwork and regularly mowing the law. Once transitioning to assisted living, the frequency with
which he was out in the community interacting with peers also changed. PA relied on others to
transport him to and from singing practice and other social events and recounted that
transportation was not always consistent.

PA mentioned vigorous vocal practice around Easter of 2016, as well as performing four
times on Easter day. Through the end of 2016, he appeared to be controlling his maximum
phonation time because he consistently reached 7 seconds on every trial. Even with his
accuracy of exactly 7 seconds, PA denied intentionally keeping time in his head. During 2016,
little variability was reported even when singing more during holiday seasons. He maintained
physical therapy throughout 2016 and results were unremarkable. No other particular events
were noted.
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Beginning in 2017, PA began noticing slight weight gain. He felt that excess weight could
be affecting his ability to generate adequate breath support, and by extension, affect his singing.
He reported decreased activity level after moving but he continued with physical therapy
throughout the year. His maximum phonation time became more variable beginning in early
2017. While his average still maintained 7 seconds, his range was between 5-7 seconds, except
surrounding Easter 2017.
On April 17, 2017, PA’s MPT was 11 seconds, significantly longer in than the prior
months. He reported singing multiple times over the weekend for Easter church services. His
facial expression and movement showed improvement from prior session when a slight left
eyelid droop and masked expression were more prominent. Later in the month, PA stated he
had almost completed PT but reported they injured his legs. Specifics of the injury were not
shared.

Following his injury, mobility continued to decline. He did not seek assistance from a
walker at this time. There were no vocal quality changes that were noted until August 2017,
when patient experienced pitch break during the session, which was uncharacteristic for PA.
August 21, 2017, PA demonstrated a significant change in vocal quality with wet hoarseness
during the session due to excess secretions. His GRBAS scale was: G1R1B1A1S0. Though he
was still audible and intelligible, he exhibited decreased ROM and reduced loudness when
compared to prior session. A significant reduction in pitch range and amplitude range was
observed. Continued decrease of mobility reported at this session.

PA exhibited and reported increased management of secretions in September 2017 but
noted still not feeling his voice was “back to normal.” Spouse reports increased difficulty
understanding him when they are home. His GRBAS scale was G1R0B1A1S0. The wet
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hoarseness observed at the prior session ceased but PA was quieter in conversation than
previous sessions. His MPT was 6-7 seconds and clinician recommended ENT examination.
At the start of 2018, PA ceased driving as he had been “passing out” with no known
cause and he began to use a walker regularly for safety. Clinician noted cognitive issues,
particularly with his memory, in early 2018 sessions. On April 6, 2018, PA demonstrated
relatively consistent perceptual measures. His maximum phonation time was 6 seconds, again
ranging from 5-7 seconds across various vowels. Despite patient feeling like he was unable to
gain adequate breath support, clinician noted proper abdominal breathing. By May 2018 his
condition declined more significantly. He became incontinent and soon after entered a memory
care center. His maximum phonation time was 4.8 seconds while sitting, which ranged from 4.55 seconds. He attempted a longer duration when standing and sustained phonation for 6
seconds (range 5-6), while showing a steady decrease in amplitude at 3 seconds.

Across all sessions, the main variability in PA’s performance on maximum phonation
time was shown during periods of sickness or medication changes. As PA’s cognition declined
toward the end of the project, along followed the accuracy of report. His actual move date to the
memory care center was undetermined. He reported a decrease in singing groups due to
difficulty with transportation and arranging a ride to and from rehearsals. Data collection finally
ceased when PA moved to Texas for family and financial reasons.

Results

The two types of data collected and analyzed were the objective measures of pitch and
amplitude range, and the subjective measures of any contributing variables to vocal
performance including frequency of singing, health, social, and environmental factors.
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The overall trend of the frequency range is a shallow arc, starting low prior to LSVT®,
increasing, then decreasing again toward the end of the project. The mean frequency range of
healthy controls, as listed above, is 735 Hz (Hallin et al. 2012). PA’s frequency ranges vary from
199.4 - 314.22, which is lower than the mean. The mean minimum and maximum frequencies of
the Hallin et al. (2012) study are 76.4 Hz (SD 12.33) and 811.3 Hz (SD 209.21) respectively.
PA’s minimum frequency is within 1 SD of the study mean at 69.3 Hz, but his maximum
frequency lies below the healthy controls at 392.0 Hz.
The amplitude ranges also showed areas of increase and decline, but unlike frequency,
amplitude range was overall a slight decline. PA’s amplitude range began at a range of 58 dB
and ended at a range of 32 dB. The mean for intensity range as shown by Hallin et al. (2012) is
67.7 dB (SD 4.11). PA’s amplitude ranges vary from 26-58 dB and are more than 1 SD below
control norms. For minimum intensity and maximum intensity means, Hallin et al. (2012)
reported 43.6 dB (SD 3.65) and 109.3 dB (1.77), respectively. For minimum and maximum
intensity values, PA’s maximum values lie near norms shown by Hallin et al. (2012) ranging
from 96-112 dB SPL. His minimum values however are more than 2 SD above norms ranging
from 52-80 dB SPL.

Significant subjective variables reported were frequency of singing, changes in
medication, weight, and mobility as well as beginning physical and occupational therapies. PA
reported that surrounding the holidays of Easter and Christmas he consistently sang more
frequently at rehearsals and performances. Spousal report also indicated an increase in
intelligibility after beginning physical and occupational therapy and PA demonstrated an
increase in pitch range at this time.
Upon introduction of a new secretion management medication, subject exhibited a
decrease in pitch range. PA received poorer ratings on the GRBAS scale, showing an increase
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in roughness, breathiness, and asthenia and had a decrease in maximum phonation time. His
average prior to the medication change was approximately 12 seconds, and with the new
medication, his MPT was 7 seconds. His spouse reported a decrease in vocal volume in the
home and PA was observed to have increased rate of speech in his session. He described
feeling excessive dryness and an inability to perform well when singing.
Another reported variable noted was weight gain. PA recounted that he could not
maintain adequate breath during vocal tasks due to extra weight, and his performance on tasks
also decreased. Finally, when moving to an assisted living facility and frequency of activity and
mobility was reduced, subject also displayed a decrease in vocal measures. The most
significant dip in both subjective and objective measures was the voice break observed in
August of 2017. The cause of such was not determined but subject was able to regain adequate
vocal control in following sessions.
Figures 1-6 show maximum and minimum frequency in Hz, frequency range in Hz,
maximum and minimum amplitude in dB SPL and amplitude range in dB SPL, with descriptors
of notable changes in status and performance.
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410
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Maximum Frequency
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Figure 1
PA’s maximum frequency charted at each session, measured in Hz
Highest max frequency: 392 Hz; Lowest max frequency 277.18 Hz

95
90
85
80
75
70
65

Minimum Frequency

Figure 2
PA’s minimum frequency charted at each session, measured in Hz
Highest min frequency: 92.5 Hz; Lowest min frequency: 69.3 Hz
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little variation in subj. and
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increased singing
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Hz
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significant voice break
in session
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following voice break

increased singing
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new secretion
management meds,
G1B1R1A1S0, MPT:7,
began PT/OT

move to assisted living
facility, decrease in mobility
positive results from
PT/OT,
G0R0B0A0S0, MPT:7

Figure 3
PA’s frequency range at each session, measured in Hz
Maximum range: 314.22 Hz; Minimum range: 199.4 Hz

reported weight gain,
affecting respiration

leg injury from therapy;
increased singing from
Easter
MPT:11
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Figure 4
PA’s maximum amplitude at each session, measured in dB SPL
Highest max amplitude 112 dB SPL; Lowest max amplitude 96 dB SPL
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55
50

Minumum Amplitude/Energy

Figure 5
PA’s minimum amplitude at each session, measured in dB SPL
Highest min amplitude: 80 dB SPL; Lowest min amplitude: 52 dB SPL
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beginning of study,
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disease progression
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Figure 6
PA’s amplitude range at each session, measured in dB SPL.
Maximum range: 58 dB; Minimum range: 26 dB

increased singing around
Christmas, little variation in
subj. and obj. measures

significant voice break
in session
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Discussion
Although symptoms associated with Parkinson’s disease vary between individuals, voice
deficits are a consistent concern across the PD population (Miller, Noble, Jones, & Burn, 2006;
Miller, Noble, Jones, Allcock, & Burn, 2008). Not only does PD affect voice, but those voice
deficits lead into a decrease in quality of life (Shih et al. 2012). Voice therapy is the cornerstone
of speech-pathologists’ treatment for individuals with Parkinson’s disease. Researchers have
investigated therapeutic singing in lieu of LSVT®, aiming to identify a sustainable and enjoyable
therapy due to the intensive nature of LSVT®. Because singing shares similar properties with
LSVT®, including targeting vocal range and increased respiration and volume, therapeutic
singing was not a far reach from LSVT®. However, prior research on therapeutic singing either
included no measures of voice or intelligibility or they showed little gain beyond measures of
respiration (Shih et al. 2010; Stegemöller et al. 2017). Prior to this study, what had not yet been
considered was singing working in conjunction with LSVT® for therapeutic benefit.
This study is a very preliminary look into a vocal profile of a trained singer with
Parkinson’s Disease and the relationship of how proper singing can supplement LSVT® by
maintaining or even increasing vocal performance across a myriad of tasks. The primary
research question for this project was to identify if frequent singing could help maintain gains
following LSVT®. Prior to receiving therapy of any kind, PA’s voice was subjectively assessed to
be weak, unintelligible, and he reported a loss of vocal range and being short of breath. After
completing his first round of LSVT®, performance on amplitude and pitch ranges increased
slightly. Throughout the four years of data collection, though, peaks and dips occurred within
both the amplitude and frequency ranges. As shown through LSVT® research, advances from
the treatment program are generally lost after 24 months post-treatment (Ramig et al. 2001). It
is important to note that even after this two-year period, PA continued to demonstrate increases
in his frequency above baseline, implying that maintenance and even improvement was made
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at times. Though the extent of gains were not consistent, there was both subjective and
objective evidence of vocal improvement surrounding the Easter and Christmas holidays due to
increased frequency of singing.
Through comparison of PA’s frequency and amplitude ranges to vocal norms
established by Hallin et al. (2012), researchers found PA’s performance to be poorer than
controls. This was to be expected when paralleling a disordered voice to healthy individuals.
The overall trend of both amplitude and frequency ranges included a slight decline toward the
end of the project. Decline is also to be expected over a four-year period of someone with PD,
but because there are no other subjects with Parkinson’s disease to compare data, it cannot be
determined that PA’s decline is at the typical rate of individuals with PD.
When evaluating if frequency of singing affected pitch range, there were noteworthy
increases throughout the study as shown in Table 2. PA demonstrated increased pitch range
from baseline surrounding Easter when PA was singing more frequently in his church choir.
Additional singing surrounding Christmas was not shown to be as effective in increasing pitch
range to the same degree as the Easter holiday, however pitch range adjacent to Christmas still
remained above baseline, signaling vocal maintenance.
Table 2
PA pitch range (in Hz) surrounding high singing frequency holidays
Baseline

Christmas

Easter

Christmas

Easter

Christmas

Easter

Christmas

Easter

3/5/14

2014

2015

2015

2016

2016

2017

2017

2018*

218.63

233.35

304.69

266.82

261.92

233.35

228.72

241.83

223.82

*April measures not recorded; this data point from 3/2/18
There were no identifiable trends for frequency of singing and amplitude range. The
latter half of the project, intensity varied but overall decreased, and PA became less able to
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manipulate his voice to produce appropriate loud and quiet voicing in the respective conditions.
Again, this decline is to be expected due to the nature of the disease. Because PA is a
classically trained singer, it is important to note that this level of amplitude control could be
attributed PA knowing his vocal limitations and not allowing himself to push his voice beyond its
capacity. Another possible contributing factor for this variance in performance is the fact that
with PD, the primary focus is increased vocal intensity. As this is a retrospective study, the
approach at the time of data collection might have concentrated solely on increased vocal
volume during tasks. Because of this, it is possible that the full amplitude range was not
emphasized when collecting data and the subject not cued to complete his VRP using both
quiet and loud voice.
The secondary goal of this study was to explore if other social or health variables would
affect vocal performance either positively or negatively. While PA’s vocal performance, as
displayed through frequency and amplitude ranges, was not consistently affected by specific
variables, there are salient points to note. When observing what health and social/environmental
factors influence overall vocal performance as shown through intelligibility, audibility, and pitch
range, researchers found varied results.
It is difficult to show how social or health variables could positively affect voice, as the
predominant influences observed in this study were negative. When experiencing negative
physiological changes, though, PA’s vocal performance did appear to mirror that change, as
seen when PA reported a decrease in mobility. When moving to an assisted living facility and
PA noted a reduction in activity level, he demonstrated a decrease in pitch range. As noted in
the results, the introduction of a new secretion management medication also diminished his
frequency range. Maximum phonation time appeared to be significantly affected by periods of
sickness and medication changes. Inversely, when beginning preemptive treatment of PT and
OT, there was a slight increase in intelligibility as well as pitch range. At this time, there is not
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sufficient data to determine if PA’s singing performance had predictive qualities and indicated
disease progression before symptoms worsened versus singing performance simply reflecting
symptom progression of PD. Concrete conclusions about direct influence of variables such as
these cannot yet be made, however, this project does provide insight on potential variables that
can affect speech and intelligibility.
This study is unique because of the complex interaction between PA’s vocal
performance and how that ties into, not only intelligibility in conversation, but also into his
singing ability and quality of life. Though no quality of life scales were administered, PA would
be perhaps more affected by a decrease in singing performance than intelligibility in
conversation, due to his passion for singing. Also, from a technical standpoint, PA has a high
level of awareness into how his voice appears in conversation and in singing and was very
attuned to his performance and limitations. PA was the chosen subject to investigate because
he had periods of vocal maintenance even up until 4 years past the treatment. Not only did he
maintain, but he even made improvements in vocal performance and intelligibility at times.
Thus, the connection was drawn between proper singing and vocal maintenance. Because he is
highly motivated by singing, PA blends these social and physical components potentially more
so than other individuals might, which provides an invaluable perspective on this topic.
Limitations
As with any project, there are limitations to note. First, the primary limitation is that this
project is a case study (level III on levels of evidence scale). While it provides longitudinal data
on a gentleman with Parkinson’s Disease, it still remains only one individual. Had there been a
larger sample size, data could have been compared and contrasted to evaluate degree of
change or significance in measures. Also as previously stated, there is much variability in PD
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symptoms. This study maintaining its level of evidence, paired with the variability within PD,
cannot be determined to generalize to other individuals of the Parkinson’s community.
Secondly, it is a retrospective study and therefore, there was only access to the
variables collected at that time. When analyzing data, researchers were not able to include
other potential variables of interest. There were inconsistencies when tracking subjective
measures, such as intelligibility in conversation and the GRBAS scale, as well as
inconsistencies within patient report. Had this been a prospective study, structured guidelines
for data collection would have been in place, ensuring a higher quality and more effective data
pool. With more concrete and standardized variables, PA’s progress would have been more
easily tracked over time and effects potentially more substantial.
Finally, while voice range profile (VRP) measures are beneficial for providing concrete
data, one must consider patient performance on structured tasks within a clinic and how these
tasks relate to the ultimate goal of intelligibility. These types of structured tasks are not in a
naturalistic environment or necessarily generalizable to such. Individuals also tend to perform
better on tasks when they know they are being measured and VRP is a very isolated measure.
VRP was the primary data collected this project was based on but is not necessarily
generalizable to precision of speech in conversation.
Future Research
This study being a retrospective, longitudinal case study represents a research pool in
its infancy, leaving much room to grow within this topic. Although consistent gains were not
shown from increased singing practice, vocal gains and increased performance were observed
surrounding times of frequent practice. Other social and environmental factors also affected
performance on speech and singing tasks and these results may shape and inform further
studies.

33

First, it is important on all future Parkinson’s and voice research to include measures of
intelligibility. Increased intelligibility is the ultimate treatment goal of voice therapy for individuals
with Parkinson’s disease. Without assessing intelligibility, it cannot be determined that the
tested intervention was effective for improving the subjects’ speech. While this study had
periodic reports of intelligibility, it was not consistent. Vocal volume and pitch are shown to affect
one’s intelligibility, but without structured measures, it cannot be determined that simply by
improving vocal volume or pitch alone increases an individual’s ability to be understood by
others.
Secondly, increasing the number of participants beyond the level of a case study is
critical when evaluating how and what variables specifically affect voice. By conducting
structured and controlled clinical trials with more participants, researchers would be able to
better grasp the vocal profile of individuals with PD and how various environmental and social
factors affect subjects differently with tested interventions. With more participants, further
assessing therapeutic singing in conjunction with LSVT® would lend way to explore whether or
not proper, regular singing could delay the need of the next round of voice therapy. As shown in
PA, gains were maintained above baseline much longer than is typical following LSVT®.
Without added research, it cannot be determined if this approach could generalize to other
individuals with Parkinson’s disorder.
Finally, if resources allow, future research utilizing a longitudinal model would provide a
more robust understanding of vocal progression of individuals with PD. The increased sample
size paired with the longitudinal format would show variance within the PD population.
Researchers could then attempt to isolate if vocal performance on speech or singing tasks has
any predictive qualities and determine whether or not singing tasks have the potential to signal
disease progression more quickly or accurately than a decline in intelligibility. The longitudinal
design would also shed light on how voice progresses and declines in individuals with PD. Also,
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including more frequent measures, rather than simply pre- and post-test, would provide a more
accurate vocal profile, rather than a broad picture of vocal performance. With a disease that
ebbs and flows as it does, this component is especially necessary to allow for variance without
over or under-estimating disease progression and the effects of such.
Summary
This study was a retrospective, longitudinal case study that measured vocal
performance in a single subject with Parkinson’s Disease across four years. The subject
participated in LSVT® and was a classically trained singer who frequently performed in social
groups. Subjective and objective data, including voice range profile, maximum phonation time,
intelligibility in conversation, and subject report of change in health or social/environmental
status was collected and analyzed. Researchers first attempted to determine if there was any
influence of frequency of proper singing on vocal performance shown through amplitude or
frequency ranges. Secondly, researchers attempted to highlight if changes in health or
social/environmental variables affected vocal performance and how. Researchers found that
more frequent singing maintained and actually improved vocal performance on pitch range.
Negative changes in health or social factors were shown to have decreased vocal performance
and intelligibility.
In conclusion, increased frequency of singing has a positive effect on intelligibility and
vocal performance in an individual with Parkinson’s disease. If further investigated, therapeutic
singing could be an effective maintenance tool to supplement a more structured, standardized
form of treatment. It has the potential to delay the need for follow-up sessions of a structured
voice program. Secondly, as to be expected, changes in health status impact one’s voice both
positively and negatively. Any change in medication or decrease in mobility or activity was
shown to decrease vocal performance. While the results of this study are very preliminary, there
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is still much to be gleaned and investigated from this topic. Examining the influence different
variables have on the voice of one with Parkinson’s disease will one day further inform
treatment.
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